Conference Calendar - The 33rd International Papillomavirus Conference

Times are stated in CEST (GMT + 2 / UTC + 2)
Every effort has been made to convert the IPVC 2020 scientific program into a fully virtual program. Thank you to all the presenters who have submitted their recordings in advance. These are available as on-demand webcasts in the interactive program on the virtual conference platform. Please note that some presenters were not able to pre-record their presentations, therefore there are still some sessions with missing presentations.

To view the pre-conference workshops, you need to register for them separately. Please contact: reg_ipvc20@kenes.com
You will then receive an email with instructions on how to login to the workshops’ platform.

Displaying One Session

View

Clinical Science Oral Session

00750 - Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease (ID 129)

Session Type

Clinical Science Oral Session

Session Date

07/22/2020

Session Time

13:15 - 14:40

Room

Hall C

Chair(s)

Thomas R. Broker (United States of America)

Watch Stream
Session Webcast

Session Webcast

[{"name":"REAL-WORLD EVIDENCE ON CLINICAL EFFECT OF REBACIN AS A NON-INVASIVE INTERVENTION FOR HIGH-RISK HUMAN PAPILLOMAVIRUS PERSISTENT INFECTION \u003Csmall\u003E(ID 682)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":682,"presentation":"REAL-WORLD EVIDENCE ON CLINICAL EFFECT OF REBACIN AS A NON-INVASIVE INTERVENTION FOR HIGH-RISK HUMAN PAPILLOMAVIRUS PERSISTENT INFECTION \u003Csmall\u003E(ID 682)\u003C\/small\u003E","session":"Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease","presenter":"Fei Chen (China)","photo":""},"playlist":[{"name":"REAL-WORLD EVIDENCE ON CLINICAL EFFECT OF REBACIN AS A NON-INVASIVE INTERVENTION FOR HIGH-RISK HUMAN","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/129\/Fei Chen ID682.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/129\/Fei Chen ID682.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/129\/65066006.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/129\/Fei Chen ID682.vtt"}]},{"name":"PERSISTENCE OF GENOTYPE-SPECIFIC, HPV INFECTION IS ASSOCIATED WITH INCREASED CUMULATIVE INCIDENCE RATE FOR HIGH-GRADE CERVICAL DISEASE: THREE-YEAR LONGITUDINAL DATA FROM THE ONCLARITY TRIAL. \u003Csmall\u003E(ID 822)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":822,"presentation":"PERSISTENCE OF GENOTYPE-SPECIFIC, HPV INFECTION IS ASSOCIATED WITH INCREASED CUMULATIVE INCIDENCE RATE FOR HIGH-GRADE CERVICAL DISEASE: THREE-YEAR LONGITUDINAL DATA FROM THE ONCLARITY TRIAL. \u003Csmall\u003E(ID 822)\u003C\/small\u003E","session":"Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease","presenter":"Jeff Andrews (United States of America)","photo":""},"playlist":[{"name":"PERSISTENCE OF GENOTYPE-SPECIFIC, HPV INFECTION IS ASSOCIATED WITH INCREASED CUMULATIVE INCIDENCE RA","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/129\/Jeff.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/129\/Jeff.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/129\/25ED14EF.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/129\/Jeff.vtt"}]},{"name":"SEQUENCING DETECTS HUMAN PAPILLOMAVIRUS IN SOME APPARENTLY HPV-NEGATIVE INVASIVE CERVICAL CANCERS \u003Csmall\u003E(ID 765)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":765,"presentation":"SEQUENCING DETECTS HUMAN PAPILLOMAVIRUS IN SOME APPARENTLY HPV-NEGATIVE INVASIVE CERVICAL CANCERS \u003Csmall\u003E(ID 765)\u003C\/small\u003E","session":"Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease","presenter":"Camilla Lagheden (Sweden)","photo":""},"playlist":[{"name":"SEQUENCING DETECTS HUMAN PAPILLOMAVIRUS IN SOME APPARENTLY HPV-NEGATIVE INVASIVE CERVICAL CANCERS","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/129\/Camilla Lagheden - IPVC20 - Presentation 765.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/129\/Camilla Lagheden - IPVC20 - Presentation 765.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/129\/5886C8EE.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/129\/Camilla Lagheden - IPVC20 - Presentation 765.vtt"}]},{"name":"LESION-BASED ESTIMATES OF HUMAN PAPILLOMAVIRUS (HPV) PREVALENCE IN ANAL HIGH-GRADE SQUAMOUS INTRAPITHELIAL LESIONS (HSIL) IN GAY AND BISEXUAL MEN (GBM) \u003Csmall\u003E(ID 845)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":845,"presentation":"LESION-BASED ESTIMATES OF HUMAN PAPILLOMAVIRUS (HPV) PREVALENCE IN ANAL HIGH-GRADE SQUAMOUS INTRAPITHELIAL LESIONS (HSIL) IN GAY AND BISEXUAL MEN (GBM) \u003Csmall\u003E(ID 845)\u003C\/small\u003E","session":"Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease","presenter":"Monica Molano (Australia)","photo":""},"playlist":[{"name":"LESION-BASED ESTIMATES OF HUMAN PAPILLOMAVIRUS (HPV) PREVALENCE IN ANAL HIGH-GRADE SQUAMOUS INTRAPIT","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/129\/Monica Molano - IPVC20 - Presentation 845.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/129\/Monica Molano - IPVC20 - Presentation 845.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/129\/363B5F41.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/129\/Monica Molano - IPVC20 - Presentation 845.vtt"}]}]

Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease Hall C

DIAGNOSIS AND TREATMENT OF CERVICAL PRE-CANCERS IN BANGLADESH (ID 281)

Session Date

07/22/2020

Session Time

13:15 - 14:40

Room

Hall C

Session Type

Clinical Science Oral Session

Session Name

Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease

Lecture Time

13:15 - 13:27

Presenter

Ashrafun Nessa (Bangladesh)

Authors

Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease Hall C

CLINICAL FACTORS ASSOCIATED WITH HPV CLEARANCE AND TREATMENT OUTCOMES FOLLOWING SURGICAL EXCISION OF PREMALIGNANT CERVICAL LESIONS. (ID 1351)

Session Date

07/22/2020

Session Time

13:15 - 14:40

Room

Hall C

Session Type

Clinical Science Oral Session

Session Name

Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease

Lecture Time

13:27 - 13:39

Presenter

Wendy Dhlomo-Mphatswe (South Africa)

Authors

Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease Hall C

REAL-WORLD EVIDENCE ON CLINICAL EFFECT OF REBACIN AS A NON-INVASIVE INTERVENTION FOR HIGH-RISK HUMAN PAPILLOMAVIRUS PERSISTENT INFECTION (ID 682)

Session Date

07/22/2020

Session Time

13:15 - 14:40

Room

Hall C

Session Type

Clinical Science Oral Session

Session Name

Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease

Lecture Time

13:39 - 13:51

Presenter

Fei Chen (China)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease Hall C

PERSISTENCE OF GENOTYPE-SPECIFIC, HPV INFECTION IS ASSOCIATED WITH INCREASED CUMULATIVE INCIDENCE RATE FOR HIGH-GRADE CERVICAL DISEASE: THREE-YEAR LONGITUDINAL DATA FROM THE ONCLARITY TRIAL. (ID 822)

Session Date

07/22/2020

Session Time

13:15 - 14:40

Room

Hall C

Session Type

Clinical Science Oral Session

Session Name

Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease

Lecture Time

13:51 - 14:03

Presenter

Jeff Andrews (United States of America)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease Hall C

SEQUENCING DETECTS HUMAN PAPILLOMAVIRUS IN SOME APPARENTLY HPV-NEGATIVE INVASIVE CERVICAL CANCERS (ID 765)

Session Date

07/22/2020

Session Time

13:15 - 14:40

Room

Hall C

Session Type

Clinical Science Oral Session

Session Name

Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease

Lecture Time

14:03 - 14:15

Presenter

Camilla Lagheden (Sweden)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease Hall C

PROGNOSTIC FACTORS OF RECURRENCE AND PROGRESSION TO MALIGNANCY IN VAGINAL INTRAEPITHELIAL NEOPLASIA: A MULTICENTER RETROSPECTIVE ANALYSIS. (ID 884)

Session Date

07/22/2020

Session Time

13:15 - 14:40

Room

Hall C

Session Type

Clinical Science Oral Session

Session Name

Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease

Lecture Time

14:15 - 14:27

Presenter

Anna Daniela Iacobone (Italy)

Authors

Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease Hall C

LESION-BASED ESTIMATES OF HUMAN PAPILLOMAVIRUS (HPV) PREVALENCE IN ANAL HIGH-GRADE SQUAMOUS INTRAPITHELIAL LESIONS (HSIL) IN GAY AND BISEXUAL MEN (GBM) (ID 845)

Session Date

07/22/2020

Session Time

13:15 - 14:40

Room

Hall C

Session Type

Clinical Science Oral Session

Session Name

Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease

Lecture Time

14:27 - 14:39

Presenter

Monica Molano (Australia)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease Hall C

Online Chat Q&A for this session is called: CLINICAL SCIENCE ORAL SESSION 6: PROGRESSION, PROGNOSTIC FACTORS AND TREATMENT IN HPV-RELATED DISEASE. You can join the online chat Q&A and discussions for this session by going back to the Lobby and entering the Networking Lounge. Speakers are encouraged to be online in the chat room at the time this session is stated to end. All times are in CEST. (ID 1788)

Session Date

07/22/2020

Session Time

13:15 - 14:40

Room

Hall C

Session Type

Clinical Science Oral Session

Session Name

Oral Session 6: Progression, Prognostic factors and Treatment in HPV-related disease

Lecture Time

14:39 - 14:39